10,285 Shares in Mirum Pharmaceuticals, Inc. $MIRM Acquired by Toth Financial Advisory Corp

Toth Financial Advisory Corp acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,285 shares of the company’s stock, valued at approximately $1,204,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MIRM. Comerica Bank lifted its stake in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period. AQR Capital Management LLC grew its stake in shares of Mirum Pharmaceuticals by 307.3% during the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after purchasing an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Mirum Pharmaceuticals by 7.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after purchasing an additional 1,720 shares during the period. Caxton Associates LLP bought a new stake in Mirum Pharmaceuticals in the first quarter valued at about $217,000. Finally, Empowered Funds LLC increased its holdings in Mirum Pharmaceuticals by 15.4% in the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after purchasing an additional 5,120 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on MIRM shares. Citigroup restated a “market outperform” rating on shares of Mirum Pharmaceuticals in a report on Thursday. Royal Bank Of Canada lowered their price target on Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. CLSA set a $146.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. HC Wainwright reduced their price objective on shares of Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $137.31.

Insider Activity at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the completion of the transaction, the senior vice president directly owned 1,274 shares of the company’s stock, valued at $127,400. This trade represents a 96.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $98.92, for a total transaction of $1,978,400.00. Following the completion of the sale, the chief executive officer owned 194,309 shares in the company, valued at $19,221,046.28. This trade represents a 9.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 133,156 shares of company stock valued at $13,763,562. 8.32% of the stock is owned by insiders.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $97.46 on Friday. The company has a fifty day moving average price of $110.63 and a 200 day moving average price of $101.79. The firm has a market cap of $6.33 billion, a PE ratio of -6.70 and a beta of 0.52. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 1-year low of $63.23 and a 1-year high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The firm had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business’s revenue for the quarter was up 37.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.12) earnings per share. Research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.